PMID- 24665840
OWN - NLM
STAT- MEDLINE
DCOM- 20150209
LR  - 20151119
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 8
IP  - 5
DP  - 2014 Jul
TI  - Recent advances and future trends in the targeted therapy of metastatic gastric 
      cancer.
PG  - 555-69
LID - 10.1586/17474124.2014.902304 [doi]
AB  - The better understanding of the molecular mechanisms behind gastric cancer has 
      led to the development of new therapeutic strategies that are likely to improve 
      patient outcomes in the near future. Recently, targeting the HER2 and the VEGF 
      pathways with trastuzumab and ramucirumab, respectively, have been found to 
      improve survival, while directed therapies against a number of other pathways are 
      under clinical evaluation. These include the hepatocyte growth factor and its 
      receptor c-MET, the insulin-like growth factor 1, the fibroblast growth factor, 
      the mammalian target of rapamycin (mTOR), the epidermal growth factor receptor, 
      and other pathways, as well as relevant immunotherapeutic strategies. This 
      article reviews recent advances and future trends of these concepts for gastric 
      cancer and adenocarcinoma of the gastroesophageal junction.
FAU - Al-Batran, Salah-Eddin
AU  - Al-Batran SE
AD  - Krankenhaus Nordwest, UCT-University Cancer Center Frankfurt, Frankfurt am Main, 
      Germany.
FAU - Werner, Dominique
AU  - Werner D
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140325
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biomarkers, Tumor/*antagonists & inhibitors/metabolism
MH  - *Drug Design
MH  - Humans
MH  - Molecular Targeted Therapy/*trends
MH  - Signal Transduction/*drug effects
MH  - Stomach Neoplasms/*drug therapy/enzymology/secondary
MH  - Treatment Outcome
OTO - NOTNLM
OT  - biological
OT  - esophageal
OT  - esophagogastric
OT  - gastric
OT  - gastroesophageal
OT  - molecular
OT  - oesophageal
OT  - personalized
OT  - targeted
OT  - treatment
EDAT- 2014/03/29 06:00
MHDA- 2015/02/11 06:00
CRDT- 2014/03/27 06:00
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/02/11 06:00 [medline]
AID - 10.1586/17474124.2014.902304 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):555-69. doi: 
      10.1586/17474124.2014.902304. Epub 2014 Mar 25.